CannonP, AsokanA, CzechowiczA, et al.Safe and effective in vivo targeting and gene editing in hematopoietic stem cells: strategies for accelerating development. Hum Gene Ther, 2021; 32:31–42.
2.
JohnstonR. Engaging cell and gene therapists in HIV cure. Hum Gene Ther, 2021; 32:17–20.
3.
McCuneJM, TurnerEH, JiangA, et al.Bringing gene therapies for HIV disease to resource-limited parts of the world. Hum Gene Ther, 2021; 32:21–30.
4.
CornuTI, MussolinoC, MullerMC, et al.HIV gene therapy: an update. Hum Gene Ther, 2021; 32:52–65.
5.
RajawatYS, HumbertO, CookSM, et al.In vivo gene therapy for canine SCID-X1 using cocal-pseudotyped lentiviral vector. Hum Gene Ther, 2021; 32:113–127.
6.
RaiR, ThrasherAJ, CavazzaA. Gene editing for the treatment of primary immunodeficiency diseases. Hum Gene Ther, 2021; 32:43–51.
7.
HastieE, SamulskiRJ. Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success—a personal perspective. Hum Gene Ther, 2015; 26:257–265.
8.
StoneD, KenkelEJ, LoprienoMA, et al.Gene transfer in adeno-associated virus seropositive rhesus macaques following rapamycin treatment and subcutaneous delivery of AAV6, but not retargeted AAV6 vectors. Hum Gene Ther, 2021; 32:96–112.
9.
ChanutFJA, SanvitoF, FerrariG, et al.Conditioning regimens in long-term pre-clinical studies to support development of ex vivo gene therapy: review of nonproliferative and proliferative changes. Hum Gene Ther, 2021; 32:66–76.
10.
SensJ, HoffmannD, LangeL, et al.Knockout-induced pluripotent stem cells for disease and therapy modeling of IL-10-associated primary immunodeficiencies. Hum Gene Ther, 2021; 32:77–95.
